ADMETatlas — Peptide ADMET Evidence Atlas

Evidence entries

209records·52peptides

Showing reference-linked Clearance evidence with reported value, assay context, interpretation role, and reference access kept separate.

Assay context

Evidence role

All209 Curated comparable179 Reported30

#	Endpoint	Peptide		Assay context	Evidence role	Reference
1	Clearance Excretion / Persistence	ATLPC0011879	0.55-0.6 L/min	TGA Product Information 5.2 pharmacokinetic properties manual extractionplasmahumanintravenous	Comparable	Open
2	Clearance Excretion / Persistence	ATLPC0019799	170 L/h	FDA Clinical Pharmacology Review Study BA058-05-011 Table 7 manual extractionplasmahumansubcutaneoussingle dose80 mcg subcutaneous abaloparatide; normal renal function; N=8	Comparable	Open
3	Clearance Excretion / Persistence	ATLPC0022388	49.12 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 11 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
4	Clearance Excretion / Persistence	ATLPC0022388	38.24 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 71 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
5	Clearance Excretion / Persistence	ATLPC0022388	49.6 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 141 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
6	Clearance Excretion / Persistence	ATLPC0022388	48.6 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 12 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
7	Clearance Excretion / Persistence	ATLPC0022388	46.7 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 72 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
8	Clearance Excretion / Persistence	ATLPC0022388	50.2 L/h/kg	FDA Clinical Pharmacology Review Tables 4-5 manual extractionplasmahumansubcutaneousday 142 mg subcutaneous tesamorelin; healthy volunteer Study TH9507/CTR/1016	Comparable	Open
9	Clearance Excretion / Persistence	ATLPC0024280	1.2 L/h	THPdb curated therapeutic product PK entrySubcutaneous	Comparable	Open
10	Clearance Excretion / Persistence	ATLPC0024280	1.2 L/h	THPdb curated therapeutic product PK entry	Comparable	Open
11	Clearance Excretion / Persistence	ATLPC0015133	0.111 L/h	THPdb curated therapeutic product PK entry	Comparable	Open
12	Clearance Excretion / Persistence	ATLPC0015133	0.111 L/h	THPdb curated therapeutic product PK entrySubcutaneous	Comparable	Open
13	Clearance Excretion / Persistence	ATLPC0018357	range 9-25 mL/min/kg	curated therapeutic product PK entryOfficial current-label support for vasopressin clearance in vasodilatory shock patients.	Comparable	Open
14	Clearance Excretion / Persistence	ATLPC0018730	7.87 mL/min	curated therapeutic product PK entryPrimary literature supports oxytocin clearance in the same quantitative range	Comparable	Open
15	Clearance Excretion / Persistence	ATLPC0002714	13.5 mL/min/kg	curated therapeutic product PK entryOfficial label support for glucagon mean clearance.	Comparable	Open
16	Clearance Excretion / Persistence	ATLPC0011879	22 mL/min/kg	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus doserativ	Comparable	Open
17	Clearance Excretion / Persistence	ATLPC0011948	0.027 mL/min/kg	Clearance in Gottingen mini pig at 2 nmol/kg, ivporcineiv	Comparable	Open
18	Clearance Excretion / Persistence	ATLPC0004545	1.2 mL/min/kg	Clearance in human after iv administrationhumaniv	Comparable	Open
19	Clearance Excretion / Persistence	ATLPC0018730	21 mL/min/kg	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus doserativ	Comparable	Open
20	Clearance Excretion / Persistence	ATLPC0018293	9 mL/min/kg	Clearance in rat after iv dose (100 ug/kg)rativ	Comparable	Open

1–20 / 209

Measurements

Browse by ADMET domain

Evidence entries